Tokyo, July 17, 2019: Eisai has received a New Drug Approval for its in-house developed anticancer agent Halaven (eribulin mesylate)…
Shanghai, May 24, 2019: New analysis released ahead of CPhI & P-MEC China (#CPhIChina and #PMECChina) – co-organized by Informa Markets, CCCMHPIE, and…